SCHEMBL5239292

SCHEMBL5239292

Cn1c(CN2C(=O)c3ccccc3C2=O)c(OCc2cccc3ccccc23)c2cc(Cl)ccc2c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.40
EDNRA P25101 2/20 0.40
MEN1 O00255 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
ALPG P10696 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
MDM2 Q00987 1/20 0.37
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5236656 0.86 DPP4 (0.44) DPP4MEN1LMNAMAPTKMT2A
SCHEMBL7003591 0.85 DPP4 (0.54) DPP4MEN1LMNAMAPTKMT2A
SCHEMBL5237954 0.85 MEN1 (0.43) DPP4MEN1LMNAMAPTKMT2A
Hydrochloric Acid SCHEMBL5234930 0.84 DPP4 (0.53) DPP4MEN1LMNAMAPTKMT2A
SCHEMBL5240407 0.83 ALOX5AP (0.40) DPP4CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5233021 0.82 DPP4 (0.44) DPP4MEN1LMNAMAPTKMT2A
SCHEMBL5232739 0.82 DPP4 (0.47) DPP4MEN1LMNAMAPTKMT2A
SCHEMBL5236012 0.80 DPP4 (0.41) DPP4MEN1LMNAMAPTKMT2A
SCHEMBL5238403 0.80 DPP4 (0.45) DPP4MEN1LMNAMAPTKMT2A
SCHEMBL5237934 0.79 DPP4 (0.45) DPP4MEN1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 DPP4 2/4885EDNRA 948/4885MEN1 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.